摘要
研究显示,肺癌疗效的提高主要得益于临床早期诊断技术的提高以及对手术、放疗、化疗和生物治疗等疗效的早期预测。因此,寻找肿瘤特异性分子标志物,并依据分子分型制定个体化治疗策略,将有利于进一步提高肺癌综合治疗的疗效。大量研究表明,新型肿瘤标志物微RNA(micro RNAs,mi RNAs)和长链非编码RNA(long non-coding RNAs,lnc RNAs)作为调控分子,在肿瘤的恶性增殖、分化、凋亡及迁移等病理和生理过程中发挥关键作用,同时为肺癌的分子诊断和分子分型的研究提供了一个新的视角。最新研究发现,循环mi RNAs和lnc RNAs具有稳定性好和易检测的优点,其异常表达既可作为肺癌早期诊断的分子标志物,也可用于预测疗效,指导肺癌的个体化治疗。本文就循环mi RNAs和lnc RNAs在肺癌早期诊断及个体化综合治疗中的作用及临床应用的最新研究进展进行综述。
The improvement of therapeutic effi cacy of lung cancer is the result of improved diagnostic techniques and early prediction of the efficacy of surgery, radiotherapy, chemotherapy and biotherapy. Therefore, searching for new specifi c tumor biomarkers and making individualized treatment strategies based on molecular classifi cation can further improve the efficacy of comprehensive therapy of lung cancer. Many studies have demonstrated that micro RNAs（mi RNAs） and long non-coding RNAs（lnc RNAs）, which are the new tumor biomarkers, play a key role in various pathophysiologic process including malignant proliferation, differentiation, apoptosis and metastasis of tumor cells and provide a new viewpoint for molecular diagnosis and classifi cation of lung cancer. Recent studies have found that circulating mi RNAs and lnc RNAs are in good stabililty and easy to detect, and their abnormal expressions can be used as molecular markers for early diagnosis and efficacy prediction of lung cancer, and they also can be used to guide individualized treatment. This review mainly summarizes and discusses the latest progress of circulating mi RNAs and lnc RNAs in early diagnosis and individualized comprehensive treatment of lung cancer as well as their clinical application.
出处
《肿瘤》
CAS
CSCD
北大核心
2015年第5期584-591,共8页
Tumor
